Immunomodulating Agents

Agents that alter the response of the immune system by activating (IMMUNOSTIMULANT) or suppressing (IMMUNOSUPPRESSIVE) the immune system and may help the body fight cancer, infection, or other diseases.

Also Known As:

Agents, Immunomodulating; Agents, Immunomodulatory; Drugs, Immunomodulatory; Drugs, Immunomodulatory IMiD; Drugs, Immunomodulatory IMiDE; IMiDs; Immunomodulating Drugs; Immunomodulatory Agents; Immunomodulatory Compounds; Immunomodulatory Drugs; Immunomodulatory IMiD Drugs; Immunomodulatory IMiDE Drugs

Networked: 2530 relevant articles (284 outcomes, 281 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Physiological Effects of Drugs: 1
    - Immunologic Factors: 7984
      - Immunomodulating Agents: 2530
        Toll-Like Receptor Agonists: 604

Experts

1.	Anderson, Kenneth C: 27 articles (11/2021 - 05/2002)
2.	Palumbo, Antonio: 15 articles (09/2021 - 07/2008)
3.	Richardson, Paul G: 12 articles (12/2021 - 04/2009)
4.	Leleu, Xavier: 12 articles (09/2021 - 10/2012)
5.	Dimopoulos, Meletios A: 11 articles (01/2021 - 01/2005)
6.	Orlowski, Robert Z: 11 articles (01/2021 - 01/2005)
7.	Voorhees, Peter M: 10 articles (12/2021 - 07/2006)
8.	Hideshima, Teru: 10 articles (01/2021 - 05/2002)
9.	Kumar, Shaji: 9 articles (01/2022 - 01/2005)
10.	Moreau, Philippe: 9 articles (01/2022 - 07/2013)

Related Diseases

1.	Multiple Myeloma 08/01/2019 - "There are many clinical trials of multiple myeloma using IMiDs under various conditions, and most of them show the efficacy of IMiDs. " 10/01/2012 - "With the introduction of immunomodulatory drugs into the treatment protocol, the outcome of multiple myeloma patients has dramatically improved with more than 30% of patients surviving for 10 years thus shifting multiple myeloma to a treatable condition." 12/01/2016 - "In the resent years, the widespread application of immunomodulatory drugs (IMiD) have made a great progress in the treatment of multiple myeloma, greatly improved the complete remission rate and prolonged the overall survival of MM patients. " 09/20/2023 - "Therapeutic adherence and assessment of satisfaction patients with multiple myeloma treated with immunomodulatory drugs in a "real-world" study: Experiences of the Polish Myeloma Group." 01/01/2021 - "Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial."
2.	Neoplasms (Cancer) 11/05/2018 - "Improved Cancer Immunochemotherapy via Optimal Co-delivery of Chemotherapeutic and Immunomodulatory Agents." 06/01/2021 - "These efforts enable programming the pharmacodynamics, pharmacokinetics, and delivery of immunomodulatory agents/co-delivery of compounds to prime at the tumor sites for improved therapeutic benefits. " 01/22/2021 - "This review is focused on IKZF TF-related pathways in MM. In particular, we will address how the depletion of IKZF TFs exerts cytotoxic effects on MM cells, by reducing their survival and proliferation, and concomitantly potentiates the antitumor immune response, thus contributing to therapeutic efficacy of IMiDs, a cornerstone in the treatment of this neoplasia." 10/31/2020 - "Understanding the mechanisms by which RT modulates immune signaling and the key players involved in modulating the RT-mediated immune response will help to improve therapeutic efficacy and to identify novel immunomodulatory drugs that will benefit cancer patients undergoing targeted RT." 10/05/2017 - "These tumors are associated with poorer patient survival in nonintensively treated patients, which is consistent with the reduced therapeutic efficacy of microenvironment-modulating IMiDs. "
3.	Inflammation (Inflammations) 01/01/2023 - "Despite being relatively rare, CAA-ri, an aggressive subtype of CAA with vascular inflammation, has gained growing attention also because of the therapeutic efficacy of anti-inflammatory and immunomodulating drugs. " 09/01/2022 - "Nanomedicine has tremendous promise for regulating inflammation and treating IMIDs. " 01/01/2012 - "Key factors leading to improved visual outcome are absolute control of preoperative inflammation with diligent use of immunomodulatory drugs, meticulous surgery along with early detection and care of postoperative complications. " 01/01/2005 - "Despite such preclinical and human evidence for the role of inflammation and immune activation in IBS, the efficacy of anti-inflammatory and immunomodulatory agents has not been adequately investigated. " 01/01/2004 - "Immunomodulatory agents may help to limit such injury by reducing inflammation. "
4.	Infections 10/01/2022 - "Our understanding of the immune system contributions to the PCAS has expanded, with animal models detailing biologically plausible mechanisms of secondary injury, the protective effects of available immunomodulatory drugs, and how immune dysregulation underlies infection susceptibility after arrest. " 08/03/2010 - "Immunomodulatory agents that decrease immune activation may be useful in the treatment of HIV-1 infection. " 01/01/2023 - "Potential of 24-Propylcholestrol as Immunity Inducer against Infection of COVID-19 Virus: In Silico Study Immunomodulatory Drugs." 01/01/2023 - "In this interview study, we identified various reasons for continuation or temporary interruption of immunomodulatory agents during infections for both IMID patients and HCPs. " 01/01/2023 - "Exploring the perspective of patients with immune-mediated inflammatory diseases and care providers on the use of immunomodulatory drugs in infections: an interview study."
5.	Multiple Sclerosis 01/01/2012 - "The approved immunomodulatory agents for the treatment of multiple sclerosis (MS) are only partially effective. " 12/01/2019 - "This manuscript reviews the primary and secondary endpoints of pivotal phase III trials with immunomodulatory drugs in multiple sclerosis (MS). " 02/01/2012 - "Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study." 01/01/2012 - "The objective of this study was to characterize from the patient's perspective the impact of a multiple sclerosis (MS) relapse in terms of the economic cost, work and leisure productivity, functional ability, and health-related quality of life (HR-QOL), for a sample of patients with RRMS in the US treated with immunomodulatory agents. " 12/01/2008 - "In this review we summarize available data from clinical studies on clinical efficacy of immunomodulatory drugs for treating patients with multiple sclerosis."

Related Drugs and Biologics

1.	Immunomodulating Agents
2.	Proteasome Inhibitors
3.	Thalidomide (Thalomid)
4.	Lenalidomide (CC 5013)
5.	Bortezomib (Velcade)
6.	Monoclonal Antibodies
7.	Adrenal Cortex Hormones (Corticosteroids)
8.	pomalidomide
9.	Azathioprine (Imuran)
10.	Dexamethasone (Maxidex)

Related Therapies and Procedures

1.	Therapeutics
2.	Immunotherapy
3.	Drug Therapy (Chemotherapy)
4.	Stem Cell Transplantation
5.	Radiotherapy